SOLIGENIX, INC. Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand how Soligenix performed this year. Instead of digging through dense legal filings, we’ll break down what’s happening with the company so you can decide if it fits your investment goals.

1. What does this company do?

Soligenix is a biopharmaceutical company in the late stages of development. They operate through two main segments:

• Specialized BioTherapeutics: They focus on rare diseases with few treatment options. Their lead project is HyBryte™ (synthetic hypericin), a light-based therapy for a skin cancer called CTCL. They also work on a treatment for pediatric Crohn’s disease.
• Public Health Solutions: They develop vaccines and treatments for biodefense and infectious diseases, including a ricin vaccine and a treatment for melioidosis. Federal agencies, such as the NIAID and BARDA, provide most of the funding for these programs.

2. How did they perform this year?

For the year ending December 31, 2025, Soligenix earned about $1.2 million, coming almost entirely from government grants rather than product sales.

Operating expenses were $18.5 million, with $12.8 million dedicated to research and development. The company is currently funding the "FLASH2" clinical trial for HyBryte™, with results expected in the second half of 2026. These results are the deciding factor for a potential resubmission of their drug application to the FDA.

3. Financial health: The "Cash Runway"

The company is not yet profitable and reported a loss of about $17.3 million in 2025. They manage their cash through three primary channels:

• Government Funding: Multi-year federal contracts provide non-dilutive capital to cover the costs of their biodefense research.
• Investor Capital: As of March 2026, the company held approximately $8.2 million in cash. With a monthly burn rate of roughly $1.2 million, current funds are projected to last until early 2027.
• Capital Structure: There are about 10.3 million shares outstanding. Because the company lacks sales revenue, they frequently issue new shares to raise capital, which reduces the ownership percentage of existing shareholders.

4. Major wins and challenges

• The "FLASH2" Trial: Since December 2024, the company has focused on patient enrollment to ensure reliable data. Success here is the primary requirement for bringing their lead drug to market.
• Regulatory Hurdles: The FDA previously rejected the company’s drug application due to missing data. The FLASH2 trial is specifically designed to provide the safety and effectiveness evidence the FDA requires for approval.

5. Key risks for investors

• Dilution: Because the company operates at a loss, they will likely need to issue more shares to raise money before 2026 ends, which will further dilute your ownership stake.
• Clinical Success: The company’s valuation is tied heavily to HyBryte™. If the trial fails, they have no other products ready for sale, which would likely result in a significant decline in stock price.
• Funding: Government grants are subject to federal budget priorities. If biodefense spending shifts or contracts are not renewed, this revenue stream could be impacted.

6. Future outlook

The next 18 months are a critical turning point. Investors should monitor the trial results expected in mid-2026. Management is actively seeking partners to help share the costs of commercializing HyBryte™. If the trial succeeds, the company aims to secure FDA approval and transition from a research-focused firm into a commercial business.

Investor Takeaway: Soligenix is a high-risk, high-reward play centered on the success of a single clinical trial. Because they rely on government grants and share offerings to fund operations, your investment is essentially a bet on the FDA approval of HyBryte™ in 2026. If you are considering an investment, ensure you are comfortable with the potential for share dilution and the binary nature of clinical trial results.